Orchestra BioMed Holdings, Inc.

OBIO Nasdaq SEC CIK 1814114
Follow Orchestra BioMed Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $91K −89.4% vs same quarter last year
Net income −$18.8M +10% vs same quarter last year
EPS, diluted −$0.30 +25% vs same quarter last year
Operating cash flow −$19.5M −34.3% vs same quarter last year
Revenue by quarter
$253K
$868K
$836K
$861K
$30.9M
$110K
$88K
$91K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$75M−$50M−$25M$0$25M$50MFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$33.5M−$52.7M
FY24$2.6M−$61M
FY23$2.8M−$49.1M
FY22$3.5M−$33.6M
FY21-−$378.8K
FY20--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−3000%−2000%−1000%0%1000%FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2599.4%−154.7%−157.4%
FY2492.3%−2437.5%−2313.3%
FY2393.3%−1866.2%−1779.7%
FY2294%−924.3%−951.3%
FY21---
FY20---
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$49.5M
FY24−$50.8M
FY23−$46.2M
FY22−$29.9M
FY21-
FY20-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Orchestra BioMed
  • Healthcare median
−3000%−2000%−1000%0%FY20FY21FY22FY23FY24FY25
Show the numbers
YearOrchestra BioMedHealthcare median
FY25−157.4%−30.6%
FY24−2313.3%−47%
FY23−1779.7%−58%
FY22−951.3%−80.4%
FY21-−71.8%
FY20-−62.2%